Keywords
Alzheimer’s disease
Fitocanabinoide
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To describe and present the importance of Cannabidiol in the therapeutic use in Alzheimer’s disease (AD). Bibliographic review: AD is the most common form of dementia, is among the incurable diseases and is classified as neurodegenerative. Pathology that begins when some proteins are installed in the central nervous system and begin to develop physiological activities inaproprialety, with progressive loss of neurons in some regions of the brain. The therapeutic use of cannabidiol in the treatment of AD is effective as a neuroprotective, anti-inflammatory and antioxidant agent, postponing the disease. Doses of the phytocannabinoid Cannabidiol (CBD) reduce the accumulation of a protein in the brain called beta-amyloid, which is the main culprit in the onset of Alzheimer’s, as this protein affects the synapses and signals to the neuron’s inflammation cells, causing these cells to be destroyed. Final Considerations: According to research carried out on the role of cannabidiol in diseases of the Central Nervous System (CNS), CBD has the ability to reduce the symptoms of AD.
References
ABATE G, et al. Potential and Limits of Cannabinoids in Alzheimer’s Disease Therapy. Biology, 2021; 10: 542.
ALALI S, et al. Cannabidiol inhibits tau aggregation in vitro. Cells, 2021; 10(12): 3521.
ARAGÃO JA, et al. O uso de Delta-9-Hidrocannabinol (THC) e Cannabidiol (CBD) no tratamento da doença de Alzheimer: uma revisão integrativa. Editora Científica Digital, 2022; 1: 51-66.
BARBOSA MGA, et al., O uso do composto canabidiol no tratamento da doença de Alzheimer. Research, Society and Development, 2020; 9(8): e442986073.
BEZZERA LR, et al. Medicamento derivado da maconha: canabidiol e seus efeitos no tratamento de doenças do sistema nervoso. Brazilian Journal of Development, 2020; 6(12): 94755-94756.
BHUNIA S, et al. Cannabidiol for neurodegenerative disorders: A comprehensive review. Front Pharmacol., 2022; 13: 989717.
BITTES YP, et al. Uso dos canabinóides no tratamento de pessoas portadoras de Alzheimer. Revisa, 2021; 10(Esp.2): 887-99.
COLES M, et al. Therapeutic properties of multi-cannabinoid tretment strategies for Alheimer’s disease. Front Neurosci., 2022; 16: 962922.
COORAY R, et al. Current aspects of the endocannabinoid system and targeted THC and CBD phytocannabinoids as potential therapeutics for Parkinson’s and Alzheimer’s diseases: a review. Mol Neurobiol., 2020; 57(11): 4878-4890.
EHRHART J, et al. Stimulation of CB2 suppresses microglial activation. Journal of Neuroinflammation, 2005; 2: 29.
ESCRITÓRIO DAS NAÇÕES UNIDAS SOBRE DROGAS E CRIME (UNODC). World Drug Report 2017. Análise e mercado de medicamentos à base de plantas. Opiáceos, cocaína, maconha.
FRAZÃO HT, et al. O uso de cannabis medicinal em portadores de transtornos psiquiátricos: uma revisão da literatura. Revista Eletrônica Acervo Médico, 2022; 20: e11076.
HOWLETT AC, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews, 2002; 54(2): 161-202.
KIM SH, et al. A Review on Studies of Marijuana for Alzheimer’s Disease – Focusing on CBD, THC. Journal of Pharmacopuncture, 2019; 22(4): 225-230.
KUHARIC DB, et al. Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev., 2021; 9(9): CD012820.
LOPEZ JAS, et al. Chapter 13 – Alzheimer’s diaese. Handbo of Clinical Neurology, 2019; 167: 231-255.
OLIVEIRA GM, et al. Uso medicinal de canabinoides no tratamento da doença de Alzheimer. Revista Cientifica Eletrônica de Ciências Aplicadas da FAIT, 2021; 1.
PERTWEE RG, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacological Reviews, 2010; 62(4): 588-631.
SANTOS VRT, et al. O uso da cannabis no tratamento do Alzheimer. Research, Society and Development, 2022; 11(7): 28711729889.
SCHELTENS P, et al. Alzheimer’s disease. Lancet, 2021; 397(10284): 1577-1590.
SILVA AS, et al. A maconha nas perspectivas contemporâneas: benefícios e malefícios. Revista Científica da Faculdade de Educação e Meio Ambiente, 2018; 9(2): 786-795.
SILVA RRG, et al. Farmacologia do mal de Alzheimer: melhoria dos efeitos adversos e perspectivas futuras. Revista Multidebates. 2021; 5(3).
SILVESTRI C e DI MARZO V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metabolism, 2013; 17(4): 475-90.
WATT G e KARL T. In vivo evidence for therapeutic properties of Cannadiol (CBD) for Alzheimer’s disease. Front Pharmacol., 2017; 8: 20.
YANG S, et al. Cannabidiol enhances microglial beta-amyloid peptide phagocytosis and clearance via vanilloid Family type 2 channel activation. National Library Of Medicine, 2022; 23(10): 5367.
YOUSAF M, et al. Neuroprotection of cannabidiol, its synthetic derivatives and combination preparations against micróglia-mediated neuroinflammation in neurological disorders. Molecules 2022; 27(15): 4961.